已发表论文

MTHFR C677T  多态性和乳腺、卵巢癌的风险:一个包含 19,260 名患者和 26,364 名对照者的综合分析

 

Authors He L, Shen Y

Received 4 September 2016

Accepted for publication 13 November 2016

Published 6 January 2017 Volume 2017:10 Pages 227—238

DOI https://doi.org/10.2147/OTT.S121472

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Chang Liu

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu

Objective: Previous studies have found that many gene variations can be detected in both breast cancer and ovarian cancer, which is beneficial for the elaboration of the molecular origin of breast and ovarian cancer. Furthermore, many studies have explored the association of methylenetetrahydrofolate reductase (MTHFR ) C677T  polymorphism with the risk of breast cancer and/or ovarian cancer; however, the results remained inconclusive. Therefore, this study conducted a systematic review and meta-analysis to evaluate the association between MTHFR C677T  polymorphism and the risk of breast and ovarian cancer.
Materials and methods: A total of 50 studies with 19,260 cases and 26,364 controls including 39 studies for breast cancer and 8 studies for ovarian cancer were identified on searching through PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP). Allele model, dominant model, recessive model, homozygous model, and co-dominant model were applied to evaluate the association of MTHFR C677T  polymorphism with breast cancer and/or ovarian cancer risk. Moreover, the odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association between MTHFR C677T  polymorphism and breast and ovarian cancer risk.
Results: A significantly increased breast cancer risk was observed in the overall analysis (for C vs T, OR =1.19, CI: 1.12–1.28, <0.05; for CC vs TT, OR =1.20, CI: 1.10–1.23, <0.05; for (CT+CC) vs TT, OR =1.19, CI: 1.11–1.27, <0.05; for CC vs (CT+TT), OR =1.19, CI: 1.79–1.95, <0.05), while no significantly increased ovarian cancer risk was detected. In the subgroup analysis based on ethnicity, a significant association of breast cancer and/or ovarian cancer risk with MTHFR C677T  polymorphism was observed in Asians. Interestingly, there was no significant association between MTHFR C677T  polymorphism and ovarian cancer risk in Caucasians, whereas a significantly increased risk of breast cancer was found in Caucasians.
Conclusion: This meta-analysis demonstrates that MTHFR C677T  polymorphism may be a risk factor for breast and ovarian cancer, especially in Asians.
Keywords: MTHFR , C677T , polymorphism, breast cancer, ovarian cancer, meta-analysis